Edwards Lifesciences Corporation (NYSE: EW) is -32.70% lower on its value in year-to-date trading and has touched a low of $85.58 and a high of $131.73 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The EW stock was last observed hovering at around $88.83 in the last trading session, with the day’s loss setting it -1.64% off its average median price target of $119.00 for the next 12 months. It is also 32.93% off the consensus price target high of $130.00 offered by 24 analysts, but current levels are 10.11% higher than the price target low of $97.00 for the same period.
Currently trading at $87.19, the stock is -6.21% and -11.21% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.71 million and changing -1.85% at the moment leaves the stock -18.26% off its SMA200. EW registered -26.10% loss for a year compared to 6-month loss of -21.84%.
The stock witnessed a -11.53% gain in the last 1 month and extending the period to 3 months gives it a -2.41%, and is -7.52% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.28% over the week and 2.84% over the month.
Edwards Lifesciences Corporation (EW) has around 15700 employees, a market worth around $54.94B and $5.36B in sales. Current P/E ratio is 37.73 and Fwd P/E is 32.23. Profit margin for the company is 27.20%. Distance from 52-week low is 1.88% and -33.81% from its 52-week high. The company has generated returns on investments over the last 12 months (23.20%).
Edwards Lifesciences Corporation (EW) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Edwards Lifesciences Corporation (EW) is a “Overweight”. 24 analysts offering their recommendations for the stock have an average rating of 2.00, where 6 rate it as a Hold and 2 think it is a “Overweight”. 15 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Edwards Lifesciences Corporation is expected to release its quarterly report on 10/26/2022.The EPS is expected to grow by 82.80% this year.
Edwards Lifesciences Corporation (EW) Top Institutional Holders
The shares outstanding are 620.90M, and float is at 614.90M with Short Float at 0.60%.
Edwards Lifesciences Corporation (EW) Insider Activity
A total of 163 insider transactions have happened at Edwards Lifesciences Corporation (EW) in the last six months, with sales accounting for 102 and purchases happening 61 times. The most recent transaction is an insider sale by BOBO DONALD E JR,the company’sCVP,Strategy/Corp Development. SEC filings show that BOBO DONALD E JR sold 6,725 shares of the company’s common stock on Sep 08 at a price of $90.94 per share for a total of $0.61 million. Following the sale, the insider now owns 62561.0 shares.
Edwards Lifesciences Corporation disclosed in a document filed with the SEC on Sep 06 that Wood Larry L (CVP, TAVR) sold a total of 7,242 shares of the company’s common stock. The trade occurred on Sep 06 and was made at $89.00 per share for $0.64 million. Following the transaction, the insider now directly holds 0.2 million shares of the EW stock.
Still, SEC filings show that on Aug 15, MUSSALLEM MICHAEL A (Chairman & CEO) disposed off 19,875 shares at an average price of $104.74 for $2.08 million. The insider now directly holds 157,353 shares of Edwards Lifesciences Corporation (EW).
Edwards Lifesciences Corporation (EW): Who are the competitors?
The company’s main competitors (and peers) include Abbott Laboratories (ABT) that is trading -18.07% down over the past 12 months and Medtronic plc (MDT) that is -31.28% lower over the same period. Stryker Corporation (SYK) is -18.77% down on the 1-year trading charts.